Evidence map›Paper›PMID 34453028›Full record

ArticleAging2021

Apatinib inhibits the proliferation of gastric cancer cells via the AKT/GSK signaling pathway

Yi Chen, Nan Chen, Jin Xu, Xindong Wang, Xiaowei Wei, Cuiju Tang, Zhong Duanmu, Junfeng Shi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yi ChenDepartment of Oncology, Nanjing Pukou Central Hospital, Pukou Branch Hospital of Jiangsu Province Hospital, Nanjing 210000, China.
Nan ChenDepartment of Outpatient, General Hospital of Eastern Theater Command, PLA, Nanjing 210002, China.
Jin XuDepartment of Thyroid and Mammary Gland Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, China.
Xindong WangDepartment of Oncology, Medical School, Southeast University, Nanjing 210009, China.
Xiaowei WeiDepartment of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, China.
Cuiju TangDepartment of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, China.
Zhong DuanmuDepartment of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, China.
Junfeng ShiDepartment of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer (GC) is the third leading cause of cancer-associated mortality globally. Although the diagnosis and therapeutic strategies for GC have improved, the prognosis for advanced gastric cancer (AGC) remains poor. Hence, the present study sought to design a zebrafish model established by microinjecting human MGC-803 GC cell line for studying personalized molecular-targeted cancer therapy. Apatinib, a novel molecular-targeted agent, was evaluated for its

Indexed as

AnimalsAntineoplastic AgentsApoptosisCell Line, TumorCell ProliferationDisease Models, AnimalGlycogen Synthase Kinase 3HumansMolecular Targeted TherapyProto-Oncogene Proteins c-aktPyridinesSignal TransductionStomach NeoplasmsXenograft Model Antitumor AssaysZebrafishAntineoplastic AgentsapatinibGlycogen Synthase Kinase 3Proto-Oncogene Proteins c-aktPyridinesAKT/GSK signalingangiogenesisapatinibgastric cancerproliferation

Identifiers

PMID34453028
PMCPMC8436942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.